Canatu Plc Names Nedal Safwat Chief Development Officer, President of Canatu Inc.

Canatu Plc announces the appointment of Dr. Nedal Safwat (PhD in biochemistry) as chief development officer of Canatu Plc and president of Canatu Inc, effective June 9, 2025.

In his new role, Dr. Safwat will lead Canatu’s Medical Diagnostics business unit and serve as a member of the Management Team.

Dr. Safwat brings more than 20 years of industry expertise in medical diagnostics and a track record in business development across leading global organizations. Most recently, he served as VP, portfolio and program management office at Cepheid (2025). Before that, he served as VP, head of molecular diagnostics sales and marketing – North America at QIAGEN (2021–2024), and VP, marketing and business development at ChromaCode, Inc. (2020–2021). He also held multiple leadership roles in product development and commercial functions at bioMérieux (2009–2020).

“Dr. Nedal Safwat’s appointment is a key milestone in establishing Canatu as a globally relevant technology company in the medical diagnostics industry,” Juha Kokkonen, CEO, Canatu Plc, said. “Under his leadership, we will accelerate the development of highly sensitive electrochemical biosensors for unmet needs and, crucially, generate a specific roadmap and products that vividly demonstrate the unique differentiations of Canatu’s CNT technology in medical diagnostics. This roadmap will also highlight how our technology can enable a broader range of diagnostic applications through key partnerships.”

“I am honored to join Canatu at this exciting stage of growth and innovation,” added Dr. Safwat. “The technology is perfectly positioned to address the increasing demand for point-of-care diagnostic tools and new medical applications.”